BIOA CLASS ACTION NOTICE: BioAge Labs Investors that Suffered Losses are Notified to Contact BFA Law before the March 10 Court Deadline (NASDAQ:BIOA)
NEW YORK, Feb. 26, 2025 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a lawsuit has been filed against BioAge Labs, Inc. (NASDAQ: BIOA) and certain of its senior executives for potential violations of the federal securities laws.
If you invested in BioAge, you are encouraged to obtain additional information by visiting https://www.bfalaw.com/cases-investigations/bioage-labs-inc.
Investors have until March 10, 2025, to ask the Court to be appointed to lead the case. The complaint asserts claims under Sections 11 and 15 of the Securities Act of 1933 on behalf of investors who purchased stock pursuant and/or traceable to BioAge's registration statement for its initial public offering held on or about September 26, 2024. The case is pending in the U.S. District Court for the Northern District of California and is captioned Soto v. BioAge Labs, Inc., et al., No. 25-cv-196.
Why was BioAge Sued under the Federal Securities Laws?
BioAge Labs, Inc. is a clinical-stage biopharmaceutical company specializing in the development of therapeutic products for metabolic diseases, with a primary focus on obesity. The Company's lead product candidate, azelaprag, is an orally available small-molecule agonist of the apelin receptor (APJ), designed to enhance weight loss.
As alleged, BioAge's IPO documents discussed its ongoing STRIDES Phase 2 trial of azelaprag in combination with GLP-1R agonists for enhanced weight loss. BioAge stated that it was collaborating with Eli Lilly and Company ('Lilly') in connection with STRIDES, and that Lilly would be advising and assisting on all aspects of the trial's design and execution. BioAge also stated that it anticipated topline results in Q3 2025 and discussed the potential for a second Phase 2 clinical trial. As alleged, BioAge's statements conveyed to investors that there were no safety concerns and that it expected top line results to meet its primary endpoint goals.
In truth, BioAge was forced to discontinue the STRIDES Phase 2 trial after several subjects exhibited elevated liver enzyme levels, indicating potential organ damage. Consequently, the Company terminated the trial and ceased further enrollment.
The Stock Declines as the Truth is Revealed
On December 6, 2024, BioAge announced that it discontinued its STRIDES Phase 2 trial for azelaprag, citing safety concerns, after liver transaminitis was observed in subjects receiving azelaprag. The Company stated that the decision to discontinue the STRIDES trial of azelaprag 'became clear' due to 'the emerging safety profile of the current doses tested[.]' This news caused the price of BioAge stock to decline over 76%, from a closing price of $20.09 per share on December 6, 2024, to $4.65 per share on December 9, 2024.
Click here for more information: .
What Can You Do?
If you invested in BioAge you may have legal options and are encouraged to submit your information to the firm.
All representation is on a contingency fee basis, there is no cost to you. Shareholders are not responsible for any court costs or expenses of litigation. The firm will seek court approval for any potential fees and expenses.
Submit your information by visiting:
Or contact:
212-789-3619
Why Bleichmar Fonti & Auld LLP?
Bleichmar Fonti & Auld LLP is a leading international law firm representing plaintiffs in securities class actions and shareholder litigation. It was named among the Top 5 plaintiff law firms by ISS SCAS in 2023 and its attorneys have been named Titans of the Plaintiffs' Bar by Law360 and SuperLawyers by Thompson Reuters. Among its recent notable successes, BFA recovered over $900 million in value from Tesla, Inc.'s Board of Directors, as well as $420 million from Teva Pharmaceutical Ind. Ltd.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
Sharps Technology CEO, Robert Hayes, to Present at the Virtual Investor Summit on June 10, 2025
Presentation to be webcast live at 10:00 AM ET NEW YORK, June 09, 2025 (GLOBE NEWSWIRE) -- Sharps Technology, Inc. (Nasdaq: 'STSS' and 'STSSW') ('Sharps'), an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart safety syringe products to the healthcare industry, today announced that Robert Hayes, CEO, will present at the Virtual Investor Summit on June 10, 2025, at 10:00 AM ET. Investors are invited to listen to the presentation and can register here. Sharps recently announced that the Company has commenced shipments under three customer orders tied to previously announced purchase agreements. These shipments represent the Company's first commercial deliveries and its transition to revenue-generating operations. All products are being manufactured and shipped from Sharps' facility in Hungary, which has undergone significant upgrades to support high-volume production. Read the update release HERE. Presentation Details: Event: Q2 Investor Summit Date & Time: 10:00 AM ET on June 10, 2025 Presenter: Robert Hayes, CEO Webcast: LINK HERE Conference Overview and Structure:The Investor Summit is an exclusive event tailored for investors focused on small- and micro-cap stocks. It offers a unique opportunity to meet with management teams from high-potential emerging companies, gain insights from industry experts, and understand how peers are navigating the current market environment. This quarter's event centers on micro-cap companies that are currently undervalued and positioned near catalyst events that could significantly accelerate their growth trajectory. Registration for Investors:To request free registration, please go to the Investor Summit website, ( and click the "Registration" button. For More Information, please visit: or, contact johnna-mae@ About Sharps Technology:Sharps Technology is an innovative medical device and pharmaceutical packaging company offering patented, best-in-class smart-safety syringe products to the healthcare industry. The Company's product lines focus on providing ultra-low waste capabilities, that incorporate syringe technologies that use both passive and active safety features. Sharps also offers products that are designed with specialized copolymer technology to support the prefillable syringe market segment. The Company has a manufacturing facility in Hungary. For additional information, please visit FORWARD-LOOKING STATEMENTS:This press release contains 'forward-looking statements'. Forward-looking statements reflect our current view about future events. When used in this press release, the words 'anticipate,' 'believe,' 'estimate,' 'expect,' 'future,' 'intend,' 'plan,' 'poised' or the negative of these terms and similar expressions, as they relate to us or our management, identify forward-looking statements. Such statements, include, but are not limited to, statements contained in this press release relating to our business strategy, our future operating results and liquidity, and capital resources outlook. Forward-looking statements are based on our current expectations and assumptions regarding our business, the economy, and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict. Our actual results may differ materially from those contemplated by the forward-looking statements. They are neither statements of historical fact nor guarantees of assurance of future performance. We caution you therefore against relying on any of these forward-looking statements. Important factors that could cause actual results to differ materially from those in the forward-looking statements include, without limitation, our ability to raise capital to fund continuing operations; our ability to protect our intellectual property rights; the impact of any infringement actions or other litigation brought against us; competition from other providers and products; our ability to develop and commercialize products and services; changes in government regulation; our ability to complete capital raising transactions; and other factors relating to our industry, our operations and results of operations. Actual results may differ significantly from those anticipated, believed, estimated, expected, intended, or planned. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We cannot guarantee future results, levels of activity, performance, or achievements. The Company assumes no obligation to update any forward-looking statements in order to reflect any event or circumstance that may arise after the date of this release. Investor Contact:Holdsworth PartnersAdam HoldsworthPhone: 917-497-9287Email: IR@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
BAE Systems, Inc. Names Tara Olivet Senior Vice President of Finance
FALLS CHURCH, Va., June 09, 2025--(BUSINESS WIRE)--BAE Systems, Inc. has named Tara Olivet as its senior vice president of Finance, effective June 7. Olivet will lead financial operations for the company's U.S.-based businesses, which generated 2024 sales of $16.85 billion and employs more than 40,000 employees across the United States, United Kingdom, and Sweden. She will also serve as a member of the BAE Systems, Inc. senior leadership team, reporting to President and CEO Tom Arseneault. "During her 20-year tenure at BAE Systems, Tara has distinguished herself as a highly accomplished and widely respected executive," said Arseneault. "Her experience, leadership, and dedication to the company's mission will continue to be foundational to our future growth and success." Olivet joined BAE Systems in 2005 and has held numerous roles across the global enterprise, most recently serving as BAE Systems, Inc.'s deputy senior vice president of Finance, and prior to that, as vice president of Finance for the Platforms & Services sector. Before that, she spent six years with BAE Systems, Inc.'s headquarters team as the vice president of Internal Audit and Controller. Olivet also served as the finance and controls director for the U.K. Aircraft Carrier Alliance, which built and delivered the Queen Elizabeth Class Carriers to the Royal Navy, among other roles. Olivet succeeds Dan Sallet, who will support special projects until his retirement in January. "I want to thank Dan for the tremendous contributions he's made to our company throughout his more than 35-year career," said Arseneault. "His exceptional work has helped BAE Systems and its employees, customers, and shareholders to thrive." Olivet holds a Master of Business Administration from Georgetown University; a Bachelor of Business Administration in finance and marketing from Ithaca College; and a Certificate in Accounting from the University of California, Berkeley. She is also a Certified Public Accountant (CPA). View source version on Contacts For more information, please contact: Veronica Bonilla, BAE SystemsMobile: @BAESystemsInc
Miami Herald
an hour ago
- Miami Herald
UNFI services disrupted by cyberattack
United Natural Foods, Inc. is dealing with "temporary disruptions" to its operations stemming from "unauthorized activity" involving its information technology systems, the grocery retailer and wholesaler disclosed in a regulatory filing Thursday. UNFI said in the filing that it took some of its systems offline as it investigates the breach, which it discovered Thursday, but did not provide details about which of its services or capabilities have been impacted. UNFI said in a statement released Monday morning that the disruption is continuing. "As soon as we discovered the activity, an investigation was initiated with the help of leading forensics experts and we have notified law enforcement. We are assessing the unauthorized activity and working to restore our systems to safely bring them back online," UNFI said in a statement. UNFI said in the regulatory filing that it has implemented workarounds to continue providing services "where possible," but did not provide additional information. The company said it is working with third-party cybersecurity experts as it looks into the cause of the incident and develops a solution. UNFI distributes groceries and nonfood products to customers at about 30,000 locations, according to its latest annual report. The company has a primary distribution arrangement with Whole Foods Market under an agreement that extends through May 2032. UNFI also runs supermarkets under banners including Cub Foods and Shoppers. The breach follows an online attack last fall that targeted systems run in the U.S. by Dutch grocery company Ahold Delhaize. That breach forced Ahold Delhaize to take e-commerce services at its Hannaford banner down for several days in addition to disrupting online operations at other chains the company runs. Copyright 2025 Industry Dive. All rights reserved.
